Centessa Pharmaceuticals plc — Director's Dealing 2021

Jun 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-06-02

Reporting Person: GOYAL ARJUN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-02	Ordinary Shares	C	3095909	—	Acquired	3095909	Indirect
2021-06-02	Ordinary Shares	C	85909	—	Acquired	85909	Indirect
2021-06-02	Ordinary Shares	P	729750	$20.00	Acquired	3825659	Indirect
2021-06-02	Ordinary Shares	P	20250	$20.00	Acquired	106159	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-29	Series A Preferred Shares	$	A	3095909	Acquired		Ordinary Shares (3095909)	Indirect
2021-01-29	Series A Preferred Shares	$	A	85909	Acquired		Ordinary Shares (85909)	Indirect
2021-06-02	Series A Preferred Shares	$	C	3095909	Disposed		Ordinary Shares (3095909)	Indirect
2021-06-02	Series A Preferred Shares	$	C	85909	Disposed		Ordinary Shares (85909)	Indirect

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.

F3: Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F5: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F6: On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.